Tagged with strategy

Mexico Karla Alcazar, Head of LATAM at Eli Lilly, discusses the company’s plans to tackle pressing regional health challenges such as obesity, diabetes, and cancer, while also highlighting the region’s critical role in Lilly’s global strategy. Alcazar offers insights into the company’s focus on innovation, diversity, and patient-centricity, as well as…

Saudi Arabia AstraZeneca has made remarkable progress over the past three years in Saudi Arabia, gaining significant leadership in therapeutic areas like oncology and respiratory care, and expansion into rare diseases. Sameh ElFangary, Country President of AstraZeneca GCC & Pakistan shares insights into the company’s strategy and strong alignment with Saudi Arabia’s…

Mexico Enrique Giraud de Haro, President & GM at Fujifilm Mexico, highlights the company’s growth alongside Fujifilm’s expansion in the region. He discusses the importance of fostering a preventive healthcare culture, especially among younger generations, and the role of innovation in Mexico’s evolving healthcare landscape.   Investing in children’s health education…

Puerto Rico Gustavo A. Hermida, President of CIC Construction Group, shares the remarkable journey of Puerto Rico’s leading general contractor. Built on a foundation of excellence in the pharmaceutical sector, CIC has successfully diversified into healthcare, hospitality, and housing while upholding its rigorous standards of safety, quality, and timely delivery. Hermida highlights…

Puerto Rico Migna Fontan, Director of Operations for Viant Medical in Puerto Rico, provides insights into the company’s evolution and its critical role in the medtech industry. Fontan discusses Viant’s journey in Puerto Rico, its transformative milestones, and its manufacturing facility’s innovative capabilities. She highlights how the island’s skilled workforce positions Puerto…

China Since raising USD 289 million in its Spring 2020 Hong Kong IPO, InnoCare Pharma has had a remarkable rise. Led by a team of Big Pharma veterans and now also listed in Shanghai, the firm has secured regulatory approvals for its BTK inhibitor for haematological cancers in mainland China and…

China US-headquartered global genomic sequencing giant Illumina has endured a tough few years. However, now that various legal wrangles over its acquisition of cancer diagnostics developer GRAIL have been largely resolved and with a new global CEO in place, the firm has outlined a new growth strategy and is predicting high…

China Eye health, despite being essential for most of us in our daily lives, receives significantly less research funding than fields like cancer or diabetes. According to IQVIA, global spending on oncology is expected to reach USD 440 billion by 2028, while ophthalmology will see just USD 38 billion. However, conditions…

China 2024 marks 30 years for Takeda in China, and the company has been outstripping the overall market to grow by double-digits in the country since 2020. Sean Shan discusses how he has led this remarkable trajectory, focusing on Takeda’s strategic vision, key product launches, and commitment to innovation. He highlights…

Puerto Rico Juan Ignacio Diddi, GM of BMS Puerto Rico & Caribbean, has over 20 years of experience in the pharmaceutical industry, having held various roles across Latin America before taking on the role leading BMS Puerto Rico and the Caribbean in 2022. He focuses on ensuring early access to therapies, fostering…

Switzerland Industry stakeholders are raising the alarm about access to innovative medicines in Switzerland. Do delays in market access compared to other countries in Europe not only threaten the health of patients in Switzerland, but the country’s status as a global biopharmaceutical R&D hub?   Major Challenges As outlined elsewhere in…

China Jens Ewert, Life Science and Health Care Industry Leader at Deloitte China, provides an in-depth analysis of the development of China’s healthcare landscape over the previous past four years. Ewert highlights key trends such as the growing role of local biopharma players, the impact of value-based pricing, and the changing…